Bukhari, 86 patient ivermectin early treatment RCT: 82% improved viral clearance [p<0.0001] https://c19p.org/bukhari
copied to clipboard
Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease
et al., medRxiv, doi:10.1101/2021.02.02.21250840 (results 1/16) (Preprint)
RCT of relatively low risk hospitalized patients with 50 ivermectin and 50 control patients showing significantly faster viral clearance with treatment. 9 patients in the treatment arm were lost to followup compared with 5 in the control arm, which could be in part due to faster recovery with treatment. There were no safety concerns. No mortality was reported. The numbers in Table 3 are the number of patients that became negative on that day, i.e., non-cumulative. SOC included vitamin C and vitamin D. NCT04392713.
|
risk of no viral clearance, 82.4% lower, RR 0.18, p < 0.001, treatment 4 of 41 (9.8%), control 25 of 45 (55.6%), NNT 2.2, day 7, primary outcome.
|
|
risk of no viral clearance, 38.7% lower, RR 0.61, p < 0.001, treatment 24 of 41 (58.5%), control 43 of 45 (95.6%), NNT 2.7, day 3.
|
| Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates |
Bukhari et al., 1/16/2021, Randomized Controlled Trial, Pakistan, South Asia, preprint, 10 authors, dosage 12mg single dose, trial NCT04392713.
Please send us corrections, updates, or comments. Vaccines and
treatments are both valuable and complementary. All practical, effective, and
safe means should be used. No treatment, vaccine, or intervention is 100%
available and effective for all current and future variants. Denying the
efficacy of any method increases mortality, morbidity, collateral damage, and
the risk of endemic status. We do not provide medical advice. Before taking
any medication, consult a qualified physician who can provide personalized
advice and details of risks and benefits based on your medical history and
situation. FLCCC and WCH
provide treatment protocols.